Q1 Earnings Forecast for Sage Therapeutics Issued By Wedbush

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Wedbush increased their Q1 2025 EPS estimates for Sage Therapeutics in a research note issued to investors on Wednesday, November 20th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings of ($1.31) per share for the quarter, up from their previous forecast of ($1.38). Wedbush has a “Neutral” rating and a $8.00 price objective on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.50) per share. Wedbush also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.18) EPS, Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($4.83) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($0.79) EPS and FY2028 earnings at ($0.29) EPS.

Several other research analysts have also recently issued reports on SAGE. HC Wainwright reissued a “neutral” rating and issued a $14.00 price target on shares of Sage Therapeutics in a research note on Wednesday, November 20th. Truist Financial decreased their price target on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a research report on Wednesday, October 30th. Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price objective on the stock in a report on Thursday, November 21st. Bank of America lowered their price objective on shares of Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating on the stock in a research report on Wednesday, October 9th. Finally, Robert W. Baird dropped their target price on Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating on the stock in a report on Wednesday, October 9th. Three research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $12.83.

Sage Therapeutics Trading Up 9.1 %

NASDAQ SAGE opened at $5.76 on Monday. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $28.26. The stock has a market cap of $352.36 million, a price-to-earnings ratio of -1.03 and a beta of 0.92. The company has a 50-day moving average price of $6.65 and a two-hundred day moving average price of $8.95.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The company had revenue of $11.87 million during the quarter, compared to analyst estimates of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. Sage Therapeutics’s quarterly revenue was up 337.1% on a year-over-year basis. During the same period in the prior year, the business earned ($2.81) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Headlands Technologies LLC increased its position in Sage Therapeutics by 245.3% in the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 2,782 shares during the period. Lazard Asset Management LLC acquired a new position in shares of Sage Therapeutics in the 1st quarter worth approximately $127,000. Virtu Financial LLC bought a new stake in shares of Sage Therapeutics during the first quarter worth $187,000. China Universal Asset Management Co. Ltd. increased its position in Sage Therapeutics by 66.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 4,672 shares in the last quarter. Finally, Quest Partners LLC lifted its holdings in Sage Therapeutics by 14.5% during the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 1,486 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.